Table 3. Time to adjuvant endocrine therapy treatment initiation among those with stages I–III hormone receptor-positive breast cancer receiving endocrine therapy, by month of initiation.
| 0–3 Months (%) | 3–6 Months (%) | 6–9 Months (%) | 9–12 Months (%) | |
|---|---|---|---|---|
| Race/ethnicity | ||||
| Non-Hispanic white | 38.9 | 37.3 | 15.8 | 8.0 |
| Non-Hispanic black | 37.9 | 32.6 | 20.5 | 9.0 |
| Hispanic (Mexican) | 33.3 | 35.0 | 24.8 | <10.0a |
| Hispanic (South/Central) | 39.4 | 31.8 | 19.7 | <17.0 %a |
| Hispanic (other/unknown) | 31.3 | 36.0 | 19.3 | 13.3 |
| Asian | 40.5 | 34.5 | 16.4 | 8.6 |
| Age (years) | ||||
| 65–69 | 27.9 | 37.5 | 21.9 | 12.8 |
| 70–74 | 32.7 | 36.8 | 20.3 | 10.1 |
| 75–79 | 40.1 | 38.7 | 14.3 | 6.9 |
| 80+ | 37.2 | 25.3 | 15.1 | 11.3 |
| Marital status | ||||
| Married | 34.3 | 38.8 | 17.7 | 9.2 |
| Unmarried | 41.6 | 35.4 | 15.3 | 7.8 |
| Unknown | 40.5 | 33.6 | 19.5 | 6.3 |
| SES (% living below poverty) | ||||
| First tertile (<5.4 %) | 38.1 | 37.8 | 16.2 | 7.8 |
| Second tertile (5.4–11.8 %) | 36.5 | 39.1 | 16.0 | 8.5 |
| Third tertile (>11.8 %) | 40.9 | 33.3 | 17.1 | 8.7 |
| SEER Cancer Registry region | ||||
| Northeast | 41.1 | 36.1 | 15.6 | 7.2 |
| South | 46.6 | 31.7 | 14.6 | 7.1 |
| Midwest | 39.6 | 35.4 | 16.1 | 8.9 |
| West | 32.2 | 40.3 | 18.0 | 9.5 |
| Metropolitan area (yes) | 37.4 | 37.5 | 16.8 | 8.3 |
| Comorbidity scores | ||||
| 0 | 36.2 | 38.4 | 17.1 | 8.3 |
| 1 | 39.2 | 35.2 | 16.7 | 8.8 |
| 2 | 41.8 | 35.2 | 14.4 | 8.6 |
| 3+ | 49.3 | 31.0 | 13.4 | 6.2 |
| Year of diagnosis | ||||
| 2007 | 39.6 | 36.2 | 17.2 | 7.0 |
| 2008 | 37.1 | 37.6 | 16.7 | 8.6 |
| 2009 | 38.9 | 36.3 | 15.5 | 9.3 |
| AJCC tumor stage | ||||
| Stage I | 41.4 | 41.2 | 13.2 | 4.2 |
| Stage II | 35.4 | 33.7 | 19.8 | 11.1 |
| Stage III | 32.9 | 21.9 | 23.0 | 22.3 |
| Tumor size (cm) | ||||
| <1.0 | 39.0 | 40.1 | 14.8 | 6.1 |
| >=1.0 | 37.3 | 31.7 | 19.1 | 11.9 |
| Unknown size | 43.0 | 37.7 | 14.1 | 5.3 |
| Number of positive nodes | ||||
| 0 (node negative) | 39.0 | 41.5 | 14.3 | 5.2 |
| 1+ | 29.8 | 28.7 | 23.9 | 17.6 |
| Unknown | 57.2 | 26.4 | 11.5 | 4.9 |
| Tumor grade | ||||
| Well differentiated | 40.0 | 40.5 | 14.0 | 5.4 |
| Moderately differentiated | 38.4 | 37.4 | 16.2 | 8.1 |
| Poorly differentiated | 34.6 | 30.8 | 21.1 | 13.5 |
| Unknown | 46.8 | 31.0 | 14.7 | 7.4 |
| Surgery treatment | ||||
| No surgery | 67.8 | 15.4 | 12.2 | 4.7 |
| BCS | 34.5 | 41.3 | 16.7 | 7.5 |
| Mastectomy | 43.1 | 30.7 | 16.4 | 9.8 |
| Chemotherapy (yes) | ||||
| Yes | 12.2 | 22.4 | 37.1 | 28.3 |
| No | 45.7 | 40.7 | 10.8 | 2.9 |
| Radiation therapy (yes) | ||||
| Yes | 28.7 | 40.9 | 19.8 | 10.6 |
| No | 53.4 | 30.3 | 11.3 | 4.9 |
| Total | 38.5 | 36.7 | 16.5 | 8.3 |
a
Actual percentages were not reported to avoid N < 11 reporting as required by the data-user agreement